KDR and melanoma: Both activated VEGFR2 via the pro-oncogenic R1051Q mutation and the HIF-1/PDK3 bioenergetic pathway induce relevant metabolic changes in melanoma cells, serving as new targets for therapeutic intervention in melanoma (30, 31).